搜尋
Mediwound Ltd
MDWD添加自選
15.160USD
+0.340+2.29%
收盤 07/02, 13:00（美東）報價延遲15分鐘
194.84M總市值
虧損本益比TTM
關鍵數據
14.910今開
15.240最高
52.68K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.41%換手率
14.820昨收
14.710最低
699.49K成交額
虧損本益比靜
3.90市淨率
0.00%股息率 TTM
-29.90%ROA
22.50552週最高
0.88量比
-30.22M淨利潤
12.85M總股本
-2.0990每股盈餘TTM
0.18Beta
-52.35%ROE
14.14052週最低
3.58%振幅
21.90%毛利率
194.84M總市值
3.13回報/風險
2.54%風險率
TradingKey Mediwound Ltd股票評分
單位: USD 更新時間: 2026-07-02操作建議
Mediwound Ltd當前公司基本面數據相對健康，增長潛力較大。當前估值合理，在藥品行業排名79/157位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為30.17。中期看，股價處於下降通道。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Mediwound Ltd評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Mediwound Ltd亮點
亮點風險
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
業績增長期
公司處於發展階段，最新年度總收入16.96M美元
利潤高增長
公司淨利潤處於行業前列，最新年度總收入16.96M美元
估值合理
公司最新PE估值-7.22，處於3年歷史合理位
機構加倉
最新機構持股7.42M股，環比增加3.86%
分析師目標
基於
6
分析師
買入
評級
30.167
目標均價
+100.04%
漲幅空間
Mediwound Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Mediwound Ltd簡介
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
公司代碼MDWD
公司Mediwound Ltd
CEOGonen (Ofer)
網址https://www.mediwound.com/
相關品種
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52797.700
-44.800 (-0.09%)
29660.400
+349.000 (+1.19%)
7502.100
+30.600 (+0.41%)
14953.000
+150.000 (+1.01%)
69614.000
+1466.000 (+2.15%)
6391.400
+38.600 (+0.61%)
68.363
+0.019 (+0.03%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4181.520
+59.610 (+1.45%)
常見問題
Mediwound Ltd(MDWD)的當前股價是多少？
Mediwound Ltd(MDWD)的當前股價是 15.16。
Mediwound Ltd 的股票代碼是什麼？
Mediwound Ltd的股票代碼是MDWD。
Mediwound Ltd股票的52週最高點是多少？
Mediwound Ltd股票的52週最高點是22.50。
Mediwound Ltd股票的52週最低點是多少？
Mediwound Ltd股票的52週最低點是14.14。
Mediwound Ltd的市值是多少？
Mediwound Ltd的市值是194.84M。
現在Mediwound Ltd(MDWD)的股票是買入、持有還是賣出？
根據分析師評級，Mediwound Ltd(MDWD)的總體評級為買入，目標價格為30.17。
Mediwound Ltd(MDWD)股票的每股收益（EPS TTM）是多少
Mediwound Ltd(MDWD)股票的每股收益（EPS TTM）是-2.10。